Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Time to Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped down before the market opened on Monday . The stock had previously closed at $50.51, but opened at $48.2450. Zealand Pharma A/S shares last traded at $48.24, with a volume of 435 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on ZLDPF shares. Berenberg Bank lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. Jefferies Financial Group cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Wolfe Research cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th. Finally, Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Zealand Pharma A/S has a consensus rating of “Hold”.

Zealand Pharma A/S Trading Down 4.5%

The company has a debt-to-equity ratio of 0.02, a quick ratio of 37.17 and a current ratio of 37.17. The firm has a market capitalization of $3.45 billion, a PE ratio of 8.00 and a beta of 0.88. The stock’s 50-day simple moving average is $46.38 and its 200-day simple moving average is $48.73.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.